The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation

Transplant Infectious Disease

Volumn 14, Issue 2, 2012, Pages 121-131

  Fisher, R A ^a   Kistler, K D ^b   Ulsh, P ^c   Bergman, G E ^c   Morris, J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c CSL Behring LLC   (United States)

Author keywords

Acute allograft rejection; Immunoglobulins; Mortality; Outcomes; Prophylaxis

Indexed keywords

CYTOGAN; CYTOMEGALOVIRUS ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; AFRICAN AMERICAN; AGE; AGED; ALCOHOL LIVER CIRRHOSIS; ANTIVIRAL THERAPY; ARTICLE; CADAVER DONOR; CAUCASIAN; CHEMOPROPHYLAXIS; CHOLESTASIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FOLLOW UP; GENDER; GLOMERULAR FILTRATION BARRIER; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HLA MATCHING; HUMAN; LIVER CANCER; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MORTALITY; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859826578     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00664.x     Document Type: Article

References (34)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 87(7): 779-795.
2. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009; 11(3): 195-202.
3. Falagas ME, Snydman DR, George MJ, et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients: Boston Center for Liver Transplantation CMVIG Study Group. Transplantation 1996; 61(12): 1716-1720.
4. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Cytogam, MedImmune Inc. Gaithersburg, Maryland. Am J Med 1997; 103(2): 106-113.
5. Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK.A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009; 37(4): 313-319.
6. Gupta P, Hart J, Cronin D, Kelly S, Michael Millis J, Brady L. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72(6): 1098-1102.
7. Gao L-H, Zheng S-S. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol 2004; 10(13): 1857-1861.
8. Evans PC, Coleman N, Wreghitt TG, Wight DGD, Alexander GJM. Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 1999; 31(5): 913-920.
9. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8(4): 362-369.
10. Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant 2009; 9(4): 746-757.
11. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997; 126(4): 275-279.
12. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81(12): 1645-1652.
13. Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997; 63(11): 1595-1601.
14. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119(10): 984-991.
15. Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997; 11(5 Pt 1): 432-437.
16. Singh N, Wannstedt C, Keyes L, et al. Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 2004; 77(1): 106-110.
17. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4(6): 928-936.
18. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6(4): 783-790.
19. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008; 22(1): 89-97.
20. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S78-S86.
21. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1003-1019.
22. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008; 103(4): 901-910.
23. Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007; 39(10): 3204-3206.
24. Moll S, Pascualb M. Humoral rejection of organ allografts. Am J Transplant 2005; 5(11): 2611-2618.
25. Hellinger WC, Bonatti H, Machicao VI, et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clinic Proc 2006; 81(8): 1029-1033.
26. Slifkin M, Ruthazer R, Freeman R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transplant 2005; 11(12): 1597-1602.
27. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72(10): 1647-1652.
28. Snydman DR, Falagas ME, Avery R, et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001; 33(4): 2571-2575.
29. Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for cytomegalovirus prophylaxis following solid organ transplants. Cincinnati, OH: Cincinnati Children's Hospital Medical Center, 2007, p. 15.
30. Preiksaitis J, Brennan D, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5(2): 218-227.
31. [No authors listed]. Cytomegalovirus. Am J Transplant 2004; 4(Suppl 10): 51-58.
32. Griffiths P, Whitley R, Snydman D, Singh N, Boeckh M, International Herpes Management Forum. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008; 15(1): 4-12.
33. Danziger-Isakov L, Mark BG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 2009; 23(3): 295-304.
34. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG.A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8(1): 158-161.